Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium

被引：0
|
作者：
T M Beer
D C Smith
A Hussain
M Alonso
J Wang
M Giurescu
K Roth
Y Wang
机构：
[1] Knight Cancer Institute,
[2] Oregon Health & Science University,undefined
[3] University of Michigan Health System,undefined
[4] University of Maryland Medical Center,undefined
[5] Marlene and Stewart Greenebaum Cancer Center,undefined
[6] Private Hospital of Córdoba,undefined
[7] University of Nebraska Medical Center,undefined
[8] Bayer HealthCare Pharmaceuticals,undefined
[9] Astellas Pharma Global Development,undefined
来源：
British Journal of Cancer | 2012年 / 107卷
关键词：
clinical trial; phase II; epothilones; prednisone; prostatic neoplasms;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：808 / 813
页数：5
相关论文
共 50 条
  • [41] DocetaxelA Review of its Use for the First-Line Treatment of Advanced Castration-Resistant Prostate Cancer
    Kate McKeage
    Drugs, 2012, 72 : 1559 - 1577
  • [42] Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
    Omlin, Aurelius
    Cathomas, Richard
    von Amsberg, Gunhild
    Reuter, Christoph
    Feyerabend, Susan
    Loidl, Wolfgang
    Boegemann, Martin
    Lorch, Anja
    Heidenreich, Axel
    Tsaur, Igor
    Larcher-Senn, Julian
    Buck, Stefan A. J.
    Mathijssen, Ron H. J.
    Jaehde, Ulrich
    Gillessen, Silke
    Joerger, Markus
    CLINICAL CANCER RESEARCH, 2023, 29 (08) : 1887 - 1893
  • [43] Gemcitabine plus mitoxantrone and prednisone in the palliative treatment of hormone-resistant prostate cancer (HRPC): A phase II study (GOAM 01.01 study)
    Cricca, A
    Marino, A
    Valenti, D
    Melotti, B
    Amaducci, E
    Guardigli, C
    Lenzi, M
    Martorana, G
    Buli, P
    Martoni, AA
    ANTICANCER RESEARCH, 2006, 26 (3B) : 2301 - 2306
  • [44] A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
    Noguchi, Masanori
    Moriya, Fukuko
    Suekane, Shigetaka
    Ohnishi, Rei
    Matsueda, Satoko
    Sasada, Tetsuro
    Yamada, Akira
    Itoh, Kyogo
    BMC CANCER, 2013, 13
  • [45] A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
    Climent, Miguel A.
    Font, Albert
    Duran, Ignacio
    Puente, Javier
    Mendez-Vidal, Maria Jose
    Isabel Saez, Maria
    Lobera, Carmen Santander
    Arranz Arija, Jose Angel
    Gonzalez-Del-Alba, Aranzazu
    Sanchez-Hernandez, Alfredo
    Juan Fita, Maria Jose
    Esteban, Emilio
    Alonso-Gordoa, Teresa
    Mellado Gonzalez, Begona
    Maroto, Pablo
    Lazaro-Quintela, Martin
    Cassinello-Espinosa, Javier
    Perez-Valderrama, Begona
    Garcias, Carmen
    Castellano, Daniel
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : 110 - 119
  • [46] Role of the neutrophil/lymphocyte ratio in patients with metastatic castration-resistant prostate cancer treated first-line with abiraterone
    Nieblas-Toscano, D.
    Arenas-Bonilla, A. J.
    Flores-Martin, J. F.
    Gutierrez-Tejero, F.
    Velarde-Munoz, C.
    Ramos-Alaminos, C., I
    Salas-Moreno, M. C.
    Galisteo-Moya, R.
    Moreno-Jimenez, J.
    ACTAS UROLOGICAS ESPANOLAS, 2020, 44 (03): : 164 - 171
  • [47] Multiple Rechallenges for Castration-resistant Prostate Cancer Patients Responding to First-line Docetaxel: Assessment of Clinical Outcomes and Predictive Factors
    Caffo, Orazio
    Pappagallo, Giovanni
    Brugnara, Sonia
    Caldara, Alessia
    di Pasquale, Maria Chiara
    Ferro, Antonella
    Frisinghelli, Michela
    Murgia, Viviana
    Russo, Lucianna Maria
    Soini, Barbara
    Valduga, Francesco
    Veccia, Antonello
    Galligioni, Enzo
    UROLOGY, 2012, 79 (03) : 644 - 649
  • [48] A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human α? integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer
    Heidenreich, A.
    Rawal, S. K.
    Szkarlat, K.
    Bogdanova, N.
    Dirix, L.
    Stenzl, A.
    Welslau, M.
    Wang, G.
    Dawkins, F.
    de Boer, C. J.
    Schrijvers, D.
    ANNALS OF ONCOLOGY, 2013, 24 (02) : 329 - 336
  • [49] Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: A Phase II study
    Safarinejad, Mohammad Reza
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2010, 28 (01) : 21 - 27
  • [50] Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
    Rodriguez-Vida, Alejo
    Maroto, Pablo
    Font, Albert
    Martin, Cristina
    Mellado, Begona
    Corbera, Alex
    Orrillo, Mayra
    Reig, Oscar
    Querol, Rosa
    Rios-Hoyo, Alejandro
    Cano, Laia
    Alonso, Judith
    Martinez, Gemma
    Galtes, Susana
    Taus, Alvaro
    Martinez-Garcia, Maria
    Juanpere, Nuria
    Juan, Oscar
    Bellmunt, Joaquim
    BRITISH JOURNAL OF CANCER, 2023, 128 (01) : 21 - 29
12345